Search
Bezlotoxumab
go.drugbank.com/drugs/DB13140Approved[A260106] The drug was granted full approval by the EMA on January 18, 2017.[L47191] … [L46976] On November 22, 2016, the Committee for Medicinal Products for Human Use of the European Medicines Agency recommended the granting of a marketing authorization.
Methyldopa
go.drugbank.com/drugs/DB00968ApprovedInvestigational[A232224] First introduced in 1960 as an antihypertensive agent, methyldopa was considered to be useful in certain patient populations, such as pregnant women and patients with renal insufficiency. … Since then, methyldopa was largely replaced by newer, better-tolerated antihypertensive agents;[A231784] however, it is still used as monotherapy [L32614] or in combination with [hydrochlorothiazide].
Mixtures: PMS-dopazide 15 Tab, PMS-dopazide-25 TabEfbemalenograstim alfa
go.drugbank.com/drugs/DB18704ApprovedInvestigationalThis approval was contingent on positive results observed in two pivotal Phase 3 Studies GC-627-04 and GC-627-05 in the US and Europe respectively.[L48887] … [L48852,A262167] As endogenous G-CSF mediates the differentiation of hematopoietic stem cells into granulocytes and eventually neutrophils, the administration of recombinant G-CSF like efbemalenograstim
Formestane
go.drugbank.com/drugs/DB08905ApprovedWithdrawnIt is not US FDA approved, and the intramuscular injection form of formestane (Lentaron) which was approved in Europe has been withdrawn. … Some clinical data has suggested that the clinically recommended dose of 250mg was too low.
Etryptamine
go.drugbank.com/drugs/DB01546ApprovedIllicitWithdrawnSimilarly to MDMA, αET has been shown to release serotonin pre-synaptically, as well as lesser amounts of norepinephrine and dopamine. … In the 1960's, alpha-ethyltryptamine (αET), a non hydrazine reversible monoamine oxidase inhibitor, was developed in the United States by the Upjohn chemical company for use as an antidepressant. αET was
Trastuzumab deruxtecan
go.drugbank.com/drugs/DB14962ApprovedInvestigational[A188988] Trastuzumab deruxtecan was developed by Daiichi Sankyo in collaboration with AstraZeneca and was first approved by the FDA in 2019.[L10842] … [L10842] It is classified as an antibody-drug conjugate. The cleavable peptide linker used to bind the antibody and drug in this product distinguishes it from other members of its class.
Nalmefene
go.drugbank.com/drugs/DB06230ApprovedInvestigationalWithdrawn[L1024] In Europe, nalmefene oral tablets are used to reduce alcohol consumption in adults with alcohol dependence. … [L1024] Nalmefene was approved in the United States in 1995 as an antidote for opioid overdose.[A245839] Nalmefene injection is used to manage known or suspected opioid overdose.
Opium
go.drugbank.com/drugs/DB11130ApprovedIllicitDuring the years, opium was used as a sedative and hypnotic, but it was determined to be addictive.[A32171] Opium is extracted from _Papaver somniferum_, which is more known as poppies. … [L1762] Opium has gradually been superseded by a variety of synthetic opioids and general anesthetics.
Mixtures: PMS-opium and Belladona SupZinc gluconate
go.drugbank.com/drugs/DB11248ApprovedInvestigationalVet approvedIt is available as a trace mineral supplement and over the counter as a lozenge form for a reduced duration of common colds and with decreased symptom severity. … Zinc gluconate is a generally recognized as safe (GRAS) substance by FDA [L2081].
Mixtures: Children's Chew Multi & Min TabDroxidopa
go.drugbank.com/drugs/DB06262ApprovedInvestigationalEurope. … There is a deficit of noradrenaline as well as of dopamine in Parkinson's disease and it has been proposed that this underlies the sudden transient freezing seen usually in advanced disease.